Compare Stocks: TELA, LNSR, KEQU, and LUNG

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
KEQU Kewaunee Scientific	$37.78 -0.5%	$36.54	$33.27 ▼ $58.95	$108.37M	0.72	2,859 shs	1,733 shs
LNSR LENSAR	$8.30 -1.9%	$6.44	$4.95 ▼ $12.94	$101.97M	0.89	214,868 shs	142,330 shs
LUNG Pulmonx	$2.38 -1.7%	$1.73	$1.13 ▼ $2.89	$102.22M	0.28	648,131 shs	277,209 shs
TELA TELA Bio	$0.70 +7.7%	$0.74	$0.50 ▼ $1.87	$31.43M	1.34	289,968 shs	124,083 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
KEQU Kewaunee Scientific	0.00%	+1.92%	+2.55%	-7.30%	-32.35%
LNSR LENSAR	0.00%	-4.38%	+60.54%	+43.10%	-31.91%
LUNG Pulmonx	0.00%	+5.31%	+47.83%	+44.24%	+27.96%
TELA TELA Bio	0.00%	+8.31%	-1.38%	-27.84%	-60.23%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
KEQU Kewaunee Scientific	$37.78 -0.5%	$36.54	$33.27 ▼ $58.95	$108.37M	0.72	2,859 shs	1,733 shs
LNSR LENSAR	$8.30 -1.9%	$6.44	$4.95 ▼ $12.94	$101.97M	0.89	214,868 shs	142,330 shs
LUNG Pulmonx	$2.38 -1.7%	$1.73	$1.13 ▼ $2.89	$102.22M	0.28	648,131 shs	277,209 shs
TELA TELA Bio	$0.70 +7.7%	$0.74	$0.50 ▼ $1.87	$31.43M	1.34	289,968 shs	124,083 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
KEQU Kewaunee Scientific	0.00%	+1.92%	+2.55%	-7.30%	-32.35%
LNSR LENSAR	0.00%	-4.38%	+60.54%	+43.10%	-31.91%
LUNG Pulmonx	0.00%	+5.31%	+47.83%	+44.24%	+27.96%
TELA TELA Bio	0.00%	+8.31%	-1.38%	-27.84%	-60.23%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
KEQU Kewaunee Scientific	2.00	Hold	N/A	N/A
LNSR LENSAR	2.33	Hold	$11.50	38.55% Upside
LUNG Pulmonx	2.50	Moderate Buy	$7.67	222.13% Upside
TELA TELA Bio	2.40	Hold	$2.20	214.29% Upside

Current Analyst Ratings Breakdown

Latest TELA, LNSR, KEQU, and LUNG Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/25/2026	LUNG Pulmonx	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/21/2026	LNSR LENSAR	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D+) ➝ Sell (D)
8/20/2026	LNSR LENSAR	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$9.00 ➝ $10.00
8/13/2026	LNSR LENSAR	Lake Street Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$13.00
8/13/2026	LNSR LENSAR	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$7.00 ➝ $9.00
8/7/2026	LNSR LENSAR	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D+)
7/17/2026	TELA TELA Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/13/2026	LUNG Pulmonx	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/30/2026	KEQU Kewaunee Scientific	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C)

(Data available from 8/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
KEQU Kewaunee Scientific	$282M	0.38	$5.96 per share	6.34	$26.80 per share	1.41
LNSR LENSAR	$58.44M	1.75	N/A	N/A	($2.18) per share	-3.81
LUNG Pulmonx	$90.50M	1.13	N/A	N/A	$1.31 per share	1.82
TELA TELA Bio	$80.28M	0.39	N/A	N/A	$0.16 per share	4.38

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
KEQU Kewaunee Scientific	$9.62M	$3.22	11.73	N/A	N/A	3.41%	14.10%	5.55%	9/9/2026 (Estimated)
LNSR LENSAR	-$34.28M	-$0.33	N/A	N/A	N/A	57.57%	-529.08%	50.03%	11/12/2026 (Estimated)
LUNG Pulmonx	-$54M	-$1.16	N/A	N/A	N/A	-55.03%	-96.66%	-38.32%	11/11/2026 (Estimated)
TELA TELA Bio	-$38.83M	-$0.77	N/A	N/A	N/A	-51.53%	-1,320.81%	-59.39%	11/12/2026 (Estimated)

Latest TELA, LNSR, KEQU, and LUNG Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	LNSR LENSAR	-$0.1650	$0.10	+$0.2650	$0.10	$14.65 million	$16.50 million
8/10/2026	Q2 2026	TELA TELA Bio	-$0.1738	-$0.20	-$0.0262	-$0.20	$20.01 million	$19.29 million
7/29/2026	Q2 2026	LUNG Pulmonx	-$0.28	-$0.24	+$0.04	-$0.24	$22.39 million	$22.76 million
6/23/2026	Q4 2026	KEQU Kewaunee Scientific	N/A	$1.14	N/A	$1.13	N/A	$71.40 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
KEQU Kewaunee Scientific	N/A	N/A	N/A	N/A	N/A
LNSR LENSAR	N/A	N/A	N/A	N/A	N/A
LUNG Pulmonx	N/A	N/A	N/A	N/A	N/A
TELA TELA Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
KEQU Kewaunee Scientific	0.53	2.18	1.55
LNSR LENSAR	N/A	2.39	1.13
LUNG Pulmonx	0.95	4.32	3.52
TELA TELA Bio	8.82	2.99	2.38

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
KEQU Kewaunee Scientific	32.69%
LNSR LENSAR	40.15%
LUNG Pulmonx	91.04%
TELA TELA Bio	94.35%

Insider Ownership

Company	Insider Ownership
KEQU Kewaunee Scientific	14.10%
LNSR LENSAR	65.80%
LUNG Pulmonx	7.50%
TELA TELA Bio	5.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
KEQU Kewaunee Scientific	1,231	2.87 million	2.46 million	Not Optionable
LNSR LENSAR	110	12.29 million	4.20 million	Optionable
LUNG Pulmonx	250	42.95 million	39.73 million	Optionable
TELA TELA Bio	120	44.90 million	42.61 million	Optionable

TELA, LNSR, KEQU, and LUNG Headlines

Recent News About These Companies

TELA Bio (TELA) Q2 2026 Earnings Call Transcript

August 19, 2026 | finance.yahoo.com

Heather Getz Acquires 15,000 Shares of TELA Bio (NASDAQ:TELA) Stock

August 18, 2026 | insidertrades.com

Tela Bio outlines 9- to 12-month sales ramp while withdrawing full-year revenue guidance

August 12, 2026 | seekingalpha.com

TELA Bio, Inc. (TELA) Q2 2026 Earnings Call Transcript

August 11, 2026 | seekingalpha.com

TELA Bio, Inc. (TELA) Reports Q2 Loss, Lags Revenue Estimates

August 10, 2026 | zacks.com

TELA Bio Reports Second Quarter 2026 Financial Results

August 10, 2026 | markets.businessinsider.com

Tela Bio names new CEO as Malvern medtech company eyes next growth phase

August 5, 2026 | msn.com

TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 5, 2026 | globenewswire.com

Tela Bio names new CEO as co-founder exits after 14 years

August 4, 2026 | bizjournals.com

TELA Bio Appoints Heather Getz as Chief Executive Officer and Director

August 4, 2026 | quiverquant.comQ

TELA Bio Announces Appointment of Heather Getz as Chief Executive Officer and Director

August 4, 2026 | globenewswire.com

TELA Bio to Participate in the Canaccord Genuity 46th Annual Growth Conference

July 29, 2026 | globenewswire.com

TELA Bio to Announce Second Quarter 2026 Financial Results

July 20, 2026 | globenewswire.com

A perfect match

July 16, 2026 | bbc.comB

TELA Bio Healthcare Story Faces New Market Scrutiny

May 15, 2026 | kalkinemedia.comK

Earnings Release: Here's Why Analysts Cut Their TELA Bio, Inc. (NASDAQ:TELA) Price Target To US$2.25

May 15, 2026 | finance.yahoo.com

TELA Bio Inc (TELA) Q1 2026 Earnings Call Highlights: Strong European Growth and Strategic U.S. ...

May 13, 2026 | finance.yahoo.com

TELA Bio, Inc. (TELA) Q1 2026 Earnings Call Transcript

May 12, 2026 | seekingalpha.com

TELA Bio, Inc. (TELA) Reports Q1 Loss, Beats Revenue Estimates

May 12, 2026 | zacks.com

TELA Bio Reports First Quarter 2026 Financial Results

May 12, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TELA, LNSR, KEQU, and LUNG Company Descriptions

Kewaunee Scientific NASDAQ:KEQU

$37.78 -0.19 (-0.50%)

As of 08/28/2026 04:00 PM Eastern

Kewaunee Scientific Corporation designs, manufactures, and installs laboratory, healthcare, and technical furniture and infrastructure products. The company operates through two segments, Domestic and International. Its products include steel and wood casework, fume hoods, adaptable modular systems, moveable workstations, stand-alone benches, biological safety cabinets, and epoxy resin work surfaces and sinks. The company's laboratory products are used in chemistry, physics, biology, and other general science laboratories in the pharmaceutical, biotechnology, industrial, chemical, commercial, educational, government, and health care markets; and technical products are used in facilities manufacturing computers and light electronics and by users of computer and networking furniture. It sells its products primarily through dealers, its subidiaries, and a national distributor. The company was founded in 1906 and is headquartered in Statesville, North Carolina.

LENSAR NASDAQ:LNSR

$8.30 -0.16 (-1.89%)

As of 08/28/2026 04:00 PM Eastern

LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. It offers LENSAR Laser System that incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision. The company also offers ALLY Adaptive Cataract Treatment System, a platform design to femtosecond laser technology features that enhanced laser capabilities into a single small unit that allows surgeons to perform a femtosecond laser assisted cataract procedure in a single operating room. LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida.

Pulmonx NASDAQ:LUNG

$2.38 -0.04 (-1.65%)

As of 08/28/2026 04:00 PM Eastern

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. It also offers StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. The company serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.

TELA Bio NASDAQ:TELA

$0.70 +0.05 (+7.69%)

As of 08/28/2026 04:00 PM Eastern

TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TELA, LNSR, KEQU, and LUNG Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TELA, LNSR, KEQU, and LUNG Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TELA, LNSR, KEQU, and LUNG Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TELA, LNSR, KEQU, and LUNG Company Descriptions

Kewaunee Scientific NASDAQ:KEQU

LENSAR NASDAQ:LNSR

Pulmonx NASDAQ:LUNG

TELA Bio NASDAQ:TELA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TELA, LNSR, KEQU, and LUNG Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TELA, LNSR, KEQU, and LUNG Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TELA, LNSR, KEQU, and LUNG Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TELA, LNSR, KEQU, and LUNG Company Descriptions

Kewaunee Scientific NASDAQ:KEQU

LENSAR NASDAQ:LNSR

Pulmonx NASDAQ:LUNG

TELA Bio NASDAQ:TELA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools